Portfolio

revlon-logo

Revlon has developed a long-standing reputation as a color authority and beauty trendsetter in the world of color cosmetics and hair care.

vericast-logo

Vericast is reimagining marketing solutions one business-to-human connection at a time.

vtv logo

vTv Therapeutics LLC is a clinical-stage biopharmaceutical company engaged in treatments for Alzheimer’s disease and type 2 diabetes.

siga logo

SIGA is a leader in providing solutions for unmet needs in the estimated $10 billion global health security market.

Revlon

Exchange: NYSE
Symbol: REV
CEO: Debbie Perelman
HQ: New York, NY

Revlon has developed a long-standing reputation as a color authority and beauty trendsetter in the world of color cosmetics and hair care. Since its breakthrough launch of the first opaque nail enamel in 1932, Revlon has provided consumers with high quality product innovation, performance and sophisticated glamour. In 2016, Revlon acquired the iconic Elizabeth Arden® portfolio of brands, including its leading designer, heritage and celebrity fragrances. Today, the Revlon Beauty’s Group’s diversified portfolio of brands is sold in approximately 150 countries around the world in most retail distribution channels, including mass, salon and prestige. Revlon ranks among the top 20 global beauty companies, with product offerings in color cosmetics, skincare, hair color and care, beauty tools, men’s grooming products, anti-perspirant deodorants and other beauty care products fragrances under brands such as Revlon, Elizabeth Arden, Revlon ColorSilk, Revlon Professional, American Crew, Almay, Mitchum, Cutex, Elizabeth Taylor, Britney Spears, Juicy Couture, Curve, John Varvatos and Christina Aguilera.

Website: www.revlon.com

Vericast

Exchange: Privately held
Chairman and CEO: John O’Malley
HQ: San Antonio, TX

Vericast is reimagining marketing solutions one business-to-human connection at a time. By influencing how over 120 million households eat, shop, buy, save and borrow, Vericast fuels commerce, drives economic growth and directly accelerates revenue potential for thousands of brands and businesses. While its award-winning portfolio of products, technology and solutions are part of the Vericast story, its people are the true differentiators; trailblazers in data intelligence, marketing services, transaction solutions, campaign management and media delivery. For more information, visit www.vericast.com or follow Vericast on LinkedIn.

Website: https://vericast.com/

vTv Therapeutics LLC

Exchange: NASDAQ
Symbol: VTVT
President & CEO: Stephen L. Holcombe
HQ: High Point, NC

vTv Therapeutics LLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and type 2 diabetes, as well as a wide range of other diseases including central nervous system and metabolic disorders, inflammation and cancer. The company’s Phase 3 investigational therapy, azeliragon, targets a receptor in the brain, called RAGE, which is believed to play a fundamental role in Alzheimer’s disease. Scientists believe that blocking RAGE in the brain may slow the progression of clinical symptoms of the disease. There is currently no other company with a clinical stage RAGE program in Alzheimer’s disease. Additionally, vTv announced positive Phase 2 results last year for both of its lead diabetes compounds, TTP273 and TTP399, each of which demonstrated statistically significant reductions in HbA1c.

Website: www.vtvtherapeutics.com

SIGA Technologies, Inc.

Exchange: OTC
Symbol: SIGA
CEO: Phillip Gomez, Ph.D
HQ: New York, NY

SIGA is a leader in providing solutions for unmet needs in the estimated $10 billion global health security market. In 2018, the U.S. Food and Drug Administration approved SIGA’s first product, oral TPOXX® (tecovirimat), for the treatment of smallpox, a deadly bioterrorism threat that cannot be addressed through vaccines alone. SIGA has worked closely with the U.S. Government during the development of TPOXX® and has been awarded more than $1.1 billion in procurement and development contracts by the Biomedical Advanced Research and Development Authority of the U.S. Government (BARDA). Most recently, SIGA was awarded in a BARDA contract in excess of $600 million for the maintenance of 1.7 million courses of smallpox antiviral in the strategic national stockpile. SIGA is developing an intravenous formulation of TPOXX and pursuing product and market expansion opportunities including a pediatric formulation, post-exposure prophylaxis indication, and international sales.

Website: www.siga.com